London, UK, 24 March 2026 – On behalf of the Sanius Health team, I am pleased to announce the acquisition of THERAPYAUDIT, the Cambridge-based digital health company behind the beetroot® therapy audit platform used by NHS clinicians to monitor treatments, track outcomes and coordinate complex care pathways.

This acquisition expands the reach of Sanius Health technology to more than 35 NHS hospitals, strengthening our ability to support clinicians managing complex diseases including oncology, haematology, rare conditions and advanced therapies. The transaction was completed for an undisclosed cash consideration.

By bringing THERAPYAUDIT into Sanius Health, we are extending our platform to provide a broader digital infrastructure for hospitals, designed to improve care coordination, enable earlier clinical insight and support the safe management of patients living with increasingly complex conditions.

For patients and their families, this means earlier identification of complications, more effective coordination across specialist teams and improved access to innovative treatments and clinical trials. As treatment pathways become more personalised and complex, the ability to monitor therapies and outcomes in real time is becoming essential for both patient safety and long-term care management.

THERAPYAUDIT has built a strong reputation within the NHS through its beetroot® platform, which enables clinicians to track therapy delivery, measure outcomes and coordinate care across multidisciplinary teams. The system is already used by leading NHS organisations including Cambridge University Hospitals NHS Foundation Trust, Royal Papworth Hospital NHS Foundation Trust, University Hospitals Birmingham NHS Foundation Trust, Guy’s and St Thomas’ NHS Foundation Trust and Leeds Teaching Hospitals NHS Trust, among others.

Integrating THERAPYAUDIT into the Sanius ecosystem allows these therapy monitoring capabilities to be combined with AI-driven predictive analytics, longitudinal disease registries and real-world data infrastructure, creating a more connected and intelligent platform for managing complex disease.

This integration also expands the research capabilities available to clinicians and life sciences partners. By linking therapy pathway data with structured disease registries and longitudinal patient monitoring, we are able to generate deeper real-world insight into how treatments perform in routine clinical practice.

This is increasingly important as advanced therapies, biologics and precision medicines move into mainstream use. Real-world evidence generated through digital registries and therapy monitoring platforms enables clinicians, regulators and pharmaceutical companies to better understand how treatments perform outside controlled clinical trials, supporting faster research and improved long-term outcomes.

The acquisition also strengthens our presence within the UK’s life sciences ecosystem. With THERAPYAUDIT based in Cambridge, one of Europe’s leading centres for biomedical research and innovation, this expands Sanius Health’s footprint across the UK’s research corridor linking London, Cambridge and Oxford.

As we continue to scale, the combined platform will support further investment in AI-enabled care coordination, predictive clinical insight and digital infrastructure designed to help healthcare systems manage growing demand and increasingly complex treatment pathways.

Chris Wright, Founder of THERAPYAUDIT, said: “We’re delighted to welcome Sanius Health as our new co-owner. Sanius and THERAPYAUDIT share the same ambition in digital health, pushing the boundaries of technology development and deployment to enhance patient care while improving efficiency across healthcare systems.”

About Sanius Health

Sanius Health is a leading real-world evidence and patient-generated data company focused on rare and underserved conditions, developing research, evidence and data solutions for healthcare and life sciences organisations. The platform brings together hospital pathways, genomic insights and longitudinal disease management to support advanced therapies, care coordination and real-world clinical insight.

Through its rare disease and oncology registries, Sanius Health supports clinical trial recruitment, regulatory validation and reimbursement pathways, connecting healthcare providers, researchers and life sciences organisations through established research partnerships.

Combined with integration across one of the largest primary care provider footprints in the United Kingdom, the platform supports patient management, care delivery, pathway redesign, cost improvement and accelerated clinical trials, while generating decision-grade evidence for regulators, payers and life sciences partners.

The platform holds particular strength in rare diseases and haematology, with programmes across sickle cell disease (SCD), myeloproliferative neoplasms (MPNs), multiple myeloma (MM), Waldenström’s macroglobulinaemia (WM), chronic myeloid leukaemia (CML) and chronic lymphocytic leukaemia (CLL).

About THERAPY AUDIT

TherapyAudit Limited, trading as beetroot®, is a UK-based digital health company focused on improving outcomes for patients living with chronic, complex and high-risk conditions, including cancer. Established in 2006, the company supports healthcare providers to deliver safer, more proactive care by enabling earlier identification of risk, reducing avoidable complications and supporting patients to remain well outside of hospital.

Its platforms are designed to strengthen clinical oversight for patients on intensive or specialist treatments, helping teams to intervene earlier when issues arise and ensuring continuity of care across pathways. This is particularly important in oncology and other high-risk therapy areas, where timely monitoring and coordinated management can have a direct impact on patient safety, treatment adherence and overall outcomes.

By combining clinical insight with patient-centred design, beetroot® helps reduce unnecessary hospital visits, ease pressure on healthcare services and empower patients to play a more active role in their care. With operations spanning technical and commercial hubs in the UK, the company continues to work closely with healthcare systems to drive more efficient, data-informed and outcome-focused models of care.